Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Feb;42(2):183-185.
doi: 10.2337/dci18-0054.

Probing the Meaning of Persistent Propeptide Release in Type 1 Diabetes

Steven E Kahn  1   2 , Andrew T Templin  3   2 , Rebecca L Hull  3   2 , C Bruce Verchere  4
Affiliations
Comment

Probing the Meaning of Persistent Propeptide Release in Type 1 Diabetes

Steven E Kahn et al. Diabetes Care. 2019 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative pancreatic islets from a healthy individual and individuals with type 1 diabetes and type 2 diabetes. Islet amyloid is demonstrated by thioflavin S staining (green) and β-cells by insulin immunostaining (red). Scale bar = 50 µm.
See this image and copyright information in PMC

Comment on

  • Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.
    Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group. Sims EK, et al. Diabetes Care. 2019 Feb;42(2):258-264. doi: 10.2337/dc17-2625. Epub 2018 Dec 10. Diabetes Care. 2019. PMID: 30530850 Free PMC article.

Similar articles

See all similar articles

Cited by

References

    1. The DCCT Research Group Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30–36 - PubMed
    1. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989;320:550–554 - PubMed
    1. Ludvigsson J, Heding L. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabetol Lat 1982;19:351–358 - PubMed
    1. Snorgaard O, Kjems LL, Røder ME, Hartling SG, Dinesen B, Binder C. Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies. Diabetes Care 1996;19:146–150 - PubMed
    1. Sims EK, Bahnson HT, Nyalwidhe J, et al. .; T1D Exchange Residual C-peptide Study Group . Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care 2019;42:258–264 - PMC - PubMed

Publication types